期刊
CLINICAL AND EXPERIMENTAL HYPERTENSION
卷 38, 期 8, 页码 744-750出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/10641963.2016.1200063
关键词
Albuminuria; arterial stiffness; blood pressure variability; chronic kidney disease; home blood pressure; single-pill combination-based therapy
资金
- Health and Labor Sciences Research Grant
- Japan Society for the Promotion of Science (JSPS)
- SENSHIN Medical Research Foundation
- Banyu Life Science Foundation International
- Salt Science Research Foundation [1428]
- Takeda
- Daiichi Sankyo
- Kyowa-hakko Kirin
- Dainippon-Sumitomo
- Mochida
- MSD
- Pfizer
- Novartis
- Shionogi
- Astellas
- Nippon Boehringer Ingelheim
- AstraZeneka
- Grants-in-Aid for Scientific Research [15K19536, 15K09293] Funding Source: KAKEN
We examined the efficacy of single-pill irbesartan/amlodipine combination-based therapy for 12 weeks in 20 hypertensive chronic kidney disease (CKD) patients, by evaluating self-measured home blood pressure (BP) profile. The single-pill irbesartan/amlodipine combination-based therapy decreased clinic BP and home BP (morning, evening, and nighttime BPs), and improved within-visit clinic BP variability, day-by-day home BP variability (morning and evening), and nighttime home BP variability. Furthermore, the single-pill combination-based therapy reduced albuminuria and exerted improved parameters of vascular function. These results indicate that this single-pill combination-based therapy may exert beneficial effects on clinic and home BP profiles as well as on renal and vascular damages, in hypertension with CKD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据